Related Experiment Videos
[Field trial with a new human diploid cell vaccine (HDCV) against measles, mumps and rubella]
Insights
A new live attenuated human diploid cell vaccine (HDCV) for measles, mumps, and rubella shows high efficacy and safety in children. This novel vaccine demonstrated comparable immunogenic efficacy to M-M-RR II without reported side effects.
Area of Science:
- Immunology
- Vaccinology
- Pediatrics
Background:
- Measles, mumps, and rubella (MMR) are significant infectious diseases in children.
- Development of safe and effective vaccines is crucial for public health.
- Novel vaccine formulations aim to improve safety profiles and reduce contraindications.
Purpose of the Study:
- To evaluate the immunogenic efficacy and safety of a novel live attenuated human diploid cell vaccine (HDCV) against measles, mumps, and rubella.
- To compare the novel HDCV with a licensed MMR vaccine (M-M-RR II).
Main Methods:
- A double-blind field trial involving 120 children aged 15-24 months.
- Participants were randomized to receive either the novel HDCV (n=60) or M-M-RR II (n=60).
- Seroconversion rates were assessed 6-8 weeks post-vaccination; statistical analysis using the chi-squared test.
Main Results:
- High seroconversion rates (95%-100%) were observed for all vaccine components in both groups.
- No statistically significant difference in immunogenic efficacy was found between the novel HDCV and M-M-RR II (p > 0.05).
- No side effects were reported by participating physicians for the novel vaccine.
Conclusions:
- The novel live attenuated human diploid cell vaccine (HDCV) is highly efficacious and safe for measles, mumps, and rubella immunization in young children.
- The vaccine's composition, free from avian protein, animal protein extracts, and antibiotics, minimizes hypersensitivity risks.
- This HDCV presents a promising alternative for MMR vaccination, potentially broadening its applicability.
Abstract:
The results of a field trial with a novel, live attenuated human diploid cell vaccine (HDCV) against measles, mumps and rubella are described. The study was performed double blind and included 120 children aged 15 to 24 months. 60 children received the new vaccine and a control group of another 60 children were vaccinated with M-M-RR II. The seroconversion rates found 6 to 8 weeks after the vaccination were high without exception (95% to 100%). The multiple chi 2-test revealed no statistically significant difference in immunogenic efficacy between the two vaccines (p greater than 0.05). No reports of side effects were received from the 12 physicians participating in the study. It is pointed out that all components of the new vaccine are highly attenuated and that the vaccine is free of avian protein, animal protein extracts and antibiotics. This excludes all theoretical and practical contraindications due to the corresponding hypersensitivities.